MedPath

General drug use-results surveillance of Phesgo for combination subcutaneous injection MA and IN - Unresectable advanced or recurrent HER2-positive colorectal cancer that has progressed after cancer chemotherapy

Not Applicable
Recruiting
Conditions
nresectable advanced or recurrent HER2-positive colorectal cancer that has progressed after cancer chemotherapy
Registration Number
JPRN-UMIN000052965
Lead Sponsor
Chugai Pharmaceutical Co. Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

None

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath